

Hope for patients, promise for families.

Leadership Team

Linda Grais, MD
Chief Executive Officer

Stan Bukofzer, MD
Chief Medical Officer

Michael Byrnes
Chief Financial Officer

Partnering Inquiries
Akiko Shibata
Phone: 619-528-0508
ashibata@ocerainc.com

Investor Inquiries
Susan Sharpe
Phone: 919-328-1109
ssharp@ocerainc.com

Corporate Headquarters
525 University Ave, Suite 610
Palo Alto, CA 94301
650-475-0158

RTP Office
5001 S Miami Blvd, Suite 300
Durham, NC 27703
919-474-0020

www.ocerainc.com
NASDAQ: OCRX

Overview

Ocera Therapeutics' lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be a primary cause of hepatic encephalopathy (*HE*). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and has been studied by two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted fast track status by the U.S. Food and Drug Administration.

About HE

Hepatic Encephalopathy (*HE*) is a debilitating and progressive complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation, and in its more severe form, stupor, coma and even death.

Our Mission

Ocera is a clinical stage bio-pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need.

Products to Treat Acute and Chronic Orphan Liver Diseases

Ocera's drug candidate OCR-002 (ornithine phenylacetate) is an ammonia scavenger, designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis or acute liver failure. When the liver is no longer able to remove toxic substances from the blood, there is an accumulation of such toxins, particularly ammonia. Ammonia accumulation in the blood impairs brain cell function, and can lead to a neuropsychiatric condition called hepatic encephalopathy, or *HE*.

Product	Formulation	Indication	Preclinical	Phase 1	Phase 2	Phase 3
OCR-002	IV	Acute Hepatic Encephalopathy (<i>HE</i>)*	→			
		Cirrhosis and GI Bleed**	→			
		Acute Liver Failure (ALF)**	→			
	Oral	Chronic <i>HE</i>	→			

*FDA Orphan Drug and Fast Track Status

**Investigator-sponsored

This fact sheet contains forward-looking statements which reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from what is expressed in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including those risks and uncertainties discussed under "Risk Factors" in our Annual Report on form 10-K for the year ended December 31, 2015 as well as other risks detailed in our subsequent filings with the SEC. All information in this summary is as of the date of this document, and we undertake no duty to update this information unless required by law.